A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by AIO-Studien-gGmbH
Sponsor:
Collaborators:
ClinAssess GmbH
Sanofi
Information provided by (Responsible Party):
AIO-Studien-gGmbH
ClinicalTrials.gov Identifier:
NCT02166658
First received: June 16, 2014
Last updated: August 31, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)